Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2883 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Muhammad Shahzeb Khan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Duke University, Durham, NC, USA. Hauptthemen laut MEDLINE: Heart Failure, Heterocyclic Compounds, 2-Ring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Duke University, Durham, NC, USA.
- Baylor Scott and White Heart Hospital Plano, Plano, TX, USA.
- Baylor Scott and White Research Institute, Dallas, TX, USA.
- Department of Medicine, University of Mississippi, Jackson, MS, USA.
Zitieren
APA
Khan, M. S., Grayburn, P. A., & Butler, J. (2023). Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2883
Vancouver
Khan MS, Grayburn PA, Butler J. Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2883
BibTeX
@article{Khan2023,
author = {Khan, Muhammad Shahzeb and Grayburn, Paul A and Butler, Javed},
title = {Cardiac Reverse Remodelling with Vericiguat: Victory or no Victory?},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2883}
}
EUVIMED